At River BioMedics we consider it a great privilege to be working with medicinal chemist’s, Simon Macdonald PhD and Richard Hatley DPhil of RGDscience on our lead programme, a small molecule, disease modifying approach to treat heart failure with preserved ejection fraction (HFpEF). Simon and Richard have over 50 years combined experience of working with small molecules in the pharmaceutical industry at GSK and beyond. Their expertise spans medicinal chemistry, drug design and synthetic chemistry and they have extensive experience throughout the whole drug discovery process, having taken numerous programmes from Hit identification through to clinical candidate nomination.
